Certara, Inc.

Certara, Inc. Earnings Recaps

CERT Health Care 3 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 6, 2026

Certara’s shares rose 9.8% after earnings, as software growth reaccelerated to double digits and bookings increased 15%. The positive signal was tempered by services revenue declining 2% year over year and management’s view that the impact of its corrective actions will take time to show.

Key takeaways
  • Q3 revenue was $94.9 million, up 4% year over year on a continuing-operations basis; adjusted EBITDA rose 6% to $30.2 million, with a 31.8% margin.
  • Software revenue grew 11% to $48.8 million, its first double-digit organic growth quarter in two years. Software bookings increased 15% to $46.9 million.
  • Services revenue fell 2% to $46.1 million, though it grew 3.5% sequentially. Services bookings were $45.6 million, and trailing 12-month book-to-bill was 1.15.
  • Management expects new AI capabilities to contribute further to growth and positioning in 2027; nearly 10% of Phoenix Cloud accounts have migrated to the cloud so far.
Q2 2026 Aug 6, 2026

Shares declined 2.1% following Certara’s Q2 report as investors appeared unimpressed by modest revenue growth, persistent service revenue weakness, and cautious full-year guidance despite ongoing transformation efforts.

Key takeaways
  • Revenue grew 1% in Q2, with software up 4% but services down 3%, reflecting ongoing challenges in the services segment.
  • Trailing 12-month software bookings rose 7% (excluding Chemaxon), showing some momentum improvement from prior periods.
  • Services bookings remained sluggish with a 1.07 book-to-bill ratio, partly impacted by divestiture of regulatory and medical writing businesses.
  • The company reaffirmed full-year revenue growth guidance of 0% to 4%, signaling a cautious outlook.
  • Cost reduction efforts, including a 5% workforce reduction, are expected to generate $13 million in run-rate savings to support innovation investments.
Q1 2026 May 12, 2026

Shares plunged 18.7% on signs of deceleration and a cautious outlook that failed to convince investors the company can deliver durable growth despite management’s long-term ambitions.

Key takeaways
  • First quarter performance was described as "in line" with expectations but fell short of reflecting Certara’s potential, highlighting underlying growth concerns.
  • CEO emphasized restructuring and operational rigor to drive long-term growth, signaling current execution challenges.
  • The company highlighted strong regulatory foothold and scientific leadership, but these strengths alone have not translated into near-term market enthusiasm.
  • Management flagged expansion into AI-driven drug discovery as a key growth driver, yet investors appear unconvinced by the timeline or impact.
  • No specific financial metrics or margin commentary were provided to offset concerns, contributing to the negative market reaction.